Your browser doesn't support javascript.
loading
Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy and intraoperative radiation therapy in the management of gallbladder cancer: a case report.
Alaswad, Marwan; Otry, Abdullah Al; Alhosainy, Ziad; Elkordy, Fadwa; Sabbah, Belal Nedal; Arabi, Tarek Ziad; Abdulkader, Humzah; Ghanayem, Obaida Fadi; Azzam, Ayman Zaki; Amin, Tarek.
Afiliación
  • Alaswad M; College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.
  • Otry AA; College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.
  • Alhosainy Z; College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.
  • Elkordy F; College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.
  • Sabbah BN; College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.
  • Arabi TZ; College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.
  • Abdulkader H; College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.
  • Ghanayem OF; College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.
  • Azzam AZ; Department of Surgery, Surgical Oncology, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
  • Amin T; Department of General Surgery, Faculty of Medicine, Alexandria University, Alexandria, Egypt.
Front Oncol ; 14: 1361017, 2024.
Article en En | MEDLINE | ID: mdl-38634052
ABSTRACT
Gallbladder cancer (GBC) is a rare and highly aggressive malignancy, often characterized by nonspecific clinical presentations and late diagnosis, which contribute to its poor prognosis. It is commonly detected at advanced stages, leading to low survival rates. Surgical resection is the primary treatment, with the extent of surgery depending on the T stage of the cancer. In advanced cases, surgery is only considered if it can potentially be curative. Despite various treatment approaches for advanced GBC, survival outcomes remain poor. In our case series, we introduce a novel treatment approach combining cytoreductive surgery, intraoperative radiation therapy, and hyperthermic intraperitoneal chemotherapy. Remarkably, we observed a 100% one-year survival rate, with one patient achieving eight years of disease-free survival without recurrence or metastasis. This aggressive treatment strategy did not lead to increased morbidity or mortality, suggesting its safety and feasibility. However, larger-scale studies are required to draw definitive conclusions.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Front Oncol Año: 2024 Tipo del documento: Article País de afiliación: Arabia Saudita

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Front Oncol Año: 2024 Tipo del documento: Article País de afiliación: Arabia Saudita